Cardiff Oncology to Participate in the UBS Global Biopharma Conference
Cardiff Oncology, Inc. announced that its management team will present and conduct one-on-one investor meetings at the upcoming UBS Global Biopharma Conference.
Stocks · News reference
Cardiff Oncology Announces Settlement With Nerviano Medical Sciences And Amended 2017 Onvansertib License Agreement, Resolving All Litigation; Parties To Seek Dismissal With Prejudice
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer
Cardiff Oncology, Inc. has appointed Dr. Leila Alland as its interim Chief Medical Officer, succeeding Dr. Roger Sidhu.
8-K filing — Cardiff Oncology, Inc. (CRDF)
Filed: 2026-10-27 AccNo: 0001493152-26-048720 Size: 249 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia
Cardiff Oncology, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead drug candidate, onvansertib, for the treatment of chronic myelomonocytic leukemia (CMML).
HC Wainwright & Co. Upgrades Cardiff Oncology to Buy, Announces $9 Price Target
HC Wainwright & Co. analyst Robert Burns upgrades Cardiff Oncology (NASDAQ:CRDF) from Neutral to Buy and announces $9 price target.
Cardiff Oncology to Participate in September 2026 Conferences
Cardiff Oncology announced that Dr. Mani Mohindru will present at two upcoming conferences in September 2026, discussing the company's PLK1 inhibitor onvansertib for RAS-mutated metastatic colorectal cancer treatment. The company is advancing its lead asset through Phase 2 trials with positive data previously presented at ASCO.